48 results about "Carcinoma cell line" patented technology

The invention discloses an NSD3 degradation agent as well as a preparation method and application thereof, and belongs to the technical field of drug synthesis. The invention provides a compound as shown in a formula I. The compound has a good effect of degrading NSD3 protein in vitro, can inhibit proliferation of a squamous carcinoma cell line NCI-H1703, and is expected to serve as a new way for preventing and treating NSD3 related diseases. # imgabs0 #

The invention belongs to the technical field of biomedicine, and discloses an immortalized cell line for human kidney suspected cell carcinoma as well as a culture method and application of the immortalized cell line. The immortalized cell line for the human kidney suspected cell carcinoma, disclosed by the invention, is named as a human kidney suspected cell carcinoma cell line Loya a-710 (Homo sapiens), the classification name of the Latin name of the immortalized cell line is Chromophore sensor cell carcino: Loya a-710, and the preservation number of the immortalized cell line is CCTCC (China Center for Type Culture Collection) NO: C2025123. The human kidney suspected cell carcinoma cell line Loya-710 disclosed by the invention is used as an in-vitro model to rapidly grow in tissue culture, and mitochondrial mutation characteristics, a vesicle structure and a classical immunohistochemical marker of ChRCC are reserved. The invention provides a precious tool for further research on ChRCC heredity, molecules and biological characteristics, and also provides a powerful new model for mitochondrial diseases.

The invention discloses an application of indolepropionic acid in preparation of a medicine for preventing or treating ovarian cancer, the medicine takes indolepropionic acid as an active ingredient, the concentration is 0.1-1000 mu M, and the dosage forms comprise tablets, capsules, granules, pills, gels, suppositories, ointments, emulsions, mixtures, suspensions, injections and solutions. Administration routes comprise oral administration, injection administration, respiratory tract inhalation administration, local administration, sublingual administration and rectal administration, and can be combined with chemotherapeutic drugs for use. It is found through experiments that IPA with different concentrations can inhibit cell growth of ovarian cancer cell lines SKOV3 and A2780, cell proliferation of macrophages RAW264.7 is remarkably promoted, and the IPA has a potential immune promotion effect and good biological safety. In addition, the IPA can enhance the sensitivity of chemotherapeutic drugs, and the IPA and the chemotherapeutic drugs are combined to be applied to treatment of ovarian cancer, so that the treatment effect of the drugs can be remarkably improved.

The invention relates to a pharmaceutical composition for preventing and treating lung cancer, and belongs to the technical field of natural pharmaceutical compositions. In order to solve the problem that the risk of drug resistance exists when a single component of icariin is used for preventing and treating cancers, the invention provides a pharmaceutical composition for preventing and treating lung cancers, which comprises a component icariin derived from herba epimedii and a component daphnetin derived from stellera chamaejasme. The icariin and daphnoretin are compounded for preventing and treating lung cancer, and the pharmaceutical composition has the advantages of multiple components, multiple targets, small adverse reaction and synergistic interaction after compatibility. In-vitro experiments prove that through compatibility of icariin and daphnetin, proliferation, migration and invasion of lung cancer cell lines A549 and Lewis cells can be inhibited, apoptosis of the two cells is promoted, and the effect is better than that of a single icariin component. The possibility is provided for application of the icariin and daphnetin composition in lung cancer treatment, and clinical application of the icariin and daphnetin composition to lung cancer can be further developed on the basis of the anticancer effect of the composition.

The invention relates to the field of antitumor drugs, in particular to a thiophene acetyl tetrahydro-beta-carboline compound and application thereof. The thiophene acetyl tetrahydro-beta-carboline compound or the pharmaceutically acceptable salt thereof, and the pharmaceutical composition containing the compound can be used for preparing medicines for preventing and / or treating various cancers. The cancer is at least one of breast cancer, lung cancer, osteosarcoma, melanoma, gastric cancer, pancreatic cancer, kidney cancer, glioma and ovarian cancer. Activity screening is carried out on various compounds, it is found for the first time that the 12 compounds provided by the invention have remarkable broad-spectrum inhibitory activity on various human cancer cell lines, and key candidate compounds are provided for developing novel anti-cancer drugs.

The invention discloses application of vitexin (the molecular formula of the vitexin is C19H18O8, the molecular weight of the vitexin is 374.34, and the CAS number of the vitexin is 479-91-4) in preparation of antitumor drugs. The method comprises the following steps: firstly, treating esophageal cancer cell lines KYSE70 and KYSE450 with vitexin, detecting cell proliferation conditions after 0, 24 hours, 48 hours and 72 hours, and determining that the vitexin has an inhibiting effect on the esophageal cancer cell lines; the vitexin can inhibit cell proliferation of skin cancer cell lines SK-MEL-5 and SK-MEL-28 and ovarian cancer cell lines SKOV3 and TOV112D under the same concentration, and compared with a control group, the growth speed of tumor cells is remarkably reduced along with increase of the concentration of the vitexin, so that the vitexin has a remarkable effect on treating esophageal cancer, skin cancer and ovarian cancer; secondly, through a Pull down experiment, it is found that vitexin targets PRDX1, and it is indicated that vitexin can inhibit proliferation of tumor cells in vivo and in vitro by targeting PRDX1.

This invention discloses 2'-hydroxy-4,4',6'-trimethoxychalcone and 5,7,4'-trimethoxyflavanone sulfonamide derivatives, their synthesis methods and applications, belonging to the field of pharmaceutical technology, and involving two series of compounds: 3-sulfonamido-2'-hydroxy-4,4',6'-trimethoxychalcone and 8,3'-disulfonamido-5,7,4'-trimethoxyflavanone, and their preparation methods. Starting with 2-hydroxy-4,6-dimethoxyacetophenone and p-anisaldehyde or 4-methoxy-3-nitrobenzaldehyde, 2'-hydroxy-4,4',6'-trimethoxychalcone or 3-amino-2'-hydroxy-4,4',6'-trimethoxychalcone intermediates were synthesized via the Claisen-Schmidt reaction. Then, through sulfonation and intramolecular Michael addition reactions, 2'-hydroxy-4,4',6'-trimethoxychalcone and 5,7,4'-trimethoxyflavanone sulfonamide derivatives were synthesized. The preparation method is simple, mild, and yields high results. In vitro and in vivo activity tests show that the derivatives disclosed in this invention have significant in vitro inhibitory activity against gastric cancer, esophageal cancer, colorectal cancer, and lung cancer cell lines, acting as inhibitors of the protein YBX1 / RPN1. Clinically, they can be applied to targeted therapy for cancers such as gastric cancer, esophageal cancer, colorectal cancer, and lung cancer.

The application discloses a novel metabolic marker for preparing a medicine for treating liver cancer and application thereof. By constructing an ALDH6A1 overexpression liver cancer cell line, it is found through detection that the level of methylcitrate in the cell is inversely proportional to the proliferation and migration rate of liver cancer cells. In Aldh6a1 knockout mice, an AKT / NRAS liver cancer model is constructed by high-pressure tail vein injection, and it is found that the content of methylcitrate in the serum is inversely proportional to the levels of ALT and AST in the serum of the mice and inversely proportional to the liver cancer load of the mice. The metabolite methylcitrate can not only effectively inhibit the proliferation of liver cancer cells alone, but also can enhance the inhibitory effect of sorafenib on the proliferation of liver cancer cells. The metabolite can effectively inhibit the formation of tumors, can be used as a metabolic marker for detecting liver cancer, and can more accurately and efficiently judge the severity of liver cancer; and can be used as a novel metabolite for treating liver cancer, and can improve the treatment effect of liver cancer.

The invention discloses a human gallbladder cancer cell line and application thereof. The human gall bladder cancer cell line comprises a human gall bladder cancer cell JXQ-3D-8529R1 or a human gall bladder cancer cell JXQ-3D-8529R2; the human gallbladder cancer cell JXQ-3D-8529R1 is preserved in the China Center for Type Culture Collection, and the preservation number of the human gallbladder cancer cell JXQ-3D-8529R1 is CCTCC NO: C2023372; the preservation number of the human gallbladder cancer cell JXQ-3D-8529R2 is CCTCC (China Center For Type Culture Collection) NO: C2023371. The human gallbladder cancer cells JXQ-3D-8529R1 and JXQ-3D-8529R2 can be massively amplified, can be subcultured in vitro for a long time, have different sensitivities to cis-platinum, gemcitabine and the like, enrich a human gallbladder cancer cell bank, and provide a new test material for revealing the occurrence and development mechanism of gallbladder cancer and preclinical research of corresponding drug development.

The invention relates to the technical field of biology, in particular to application of free fatty acid C19: 0 in promoting esophageal cancer growth and modeling an animal tumor living body model. Results show that the free fatty acid C19: 0 has the capability of promoting proliferation, migration and invasion of esophageal cancer cells no matter in a human esophageal squamous carcinoma cell line EC109 or KYSE150; the tumor formation capability of esophageal cancer cells in nude mice can be remarkably promoted, and basic data is provided for prevention, treatment and prognosis of esophageal cancer.

The invention belongs to the technical field of biological detection and treatment, and particularly relates to an innovative application of novel circRNA: circM-TMEFF1 in diagnosis and treatment of hepatocellular carcinoma. The circM-TMEFF1 forms a ring in hepatocellular carcinoma cells, and the specificity of the circM-TMEFF1 is in low expression. The invention specifically provides application of circM-TMEFF1 as a marker in preparation of a hepatocellular carcinoma diagnosis or prognosis kit, and compared with a normal control person, the expression quantity of circM-TMEFF1 in hepatocellular carcinoma tissues and tumor recurrent tissues is remarkably reduced, so that circM-TMEFF1 can be used as a biomarker for diagnosis and prognosis of hepatocellular carcinoma. Besides, promotion of circM-TMEFF1 expression can effectively inhibit proliferation and growth of hepatocellular carcinoma cell lines, a new target is provided for improvement of treatment of hepatocellular carcinoma, and the circM-TMEFF1 has great clinical value.

The compound according to the present invention exhibits excellent anticancer effects against the triple-negative breast cancer cell line MDA-MB-231 and liver cancer cell lines as well as general cancer cell lines such as A549, SK-OV-3, SK-MEL-2, HCT15, etc., and thus can be advantageously used as an anticancer agent.

The invention belongs to the technical field of bioengineering, and discloses a method for constructing a bone-affinity mouse hepatoma cell line with bone metastasis characteristic, which comprises the following steps: digesting a mouse hepatoma cell line Hepa1-6 with pancreatin for 5 minutes, adding into a complete medium to stop digestion, centrifuging for 5 minutes at normal temperature by 300g, resuspending into 1 million cells / 100mu l by using PBS, and transferring into a 1.5 ml EP tube; after the mouse is anesthetized, shaving off hair at the chest of the mouse by using a shaver with the abdomen facing upwards, fixing the mouse on an operation table, sucking 100 [mu] l of cell suspension by using an insulin needle, inserting the needle from the intersection point of the left-side xiphoid process and the lower costal margin, and slowly injecting cells after active blood return is seen; the bone metastasis formation condition of the lower limb bone Hepa1-6 of the mouse is monitored regularly through an SPECTRAL Lago X small animal living body imaging system, isoflurane is used as an anesthetic, and it is guaranteed that the shooting time and the exposure condition of each time of monitoring are consistent; after obvious bone metastasis is formed, obvious mobility inconvenience of the mouse is observed; through multi-generation in-vivo screening, the mouse liver cancer cell line with strong bone affinity is obtained.

The invention belongs to the technical field of gene engineering and cell engineering, particularly relates to an osimertinib-resistant human lung adenocarcinoma cell line BCH-LUNK1 fused with EGFR (epidermal growth factor receptor) mutation and TPM3-NTRK1 gene, and further discloses a construction method and application of the osimertinib-resistant human lung adenocarcinoma cell line BCH-LUNK1. The human lung adenocarcinoma cell line BCH-LUNK1 disclosed by the invention is a human lung adenocarcinoma cell line with EGFR (Epidermal Growth Factor Receptor) mutation and TPM3-NTRK1 gene fusion, and is preserved in the China General Microbiological Culture Collection Center (CGMCC), and the preservation number is CGMCC No.46021. According to the invention, a stable human lung adenocarcinoma cell line is successfully established, and the cell line has EGFR19 exon mutation and TPM3-NTRK1 gene fusion at the same time, and is a good model for researching EGFR targeted therapy drug resistance mechanism, and screening and drug resistance mechanism research of NTRK targeted inhibitors.

Pediatric liver cancers (PLC) are rare tumors. In particular, hepatoblastomas are usually treated with cisplatin-based neoadjuvant chemotherapy followed by surgical removal of the tumor and adjuvant chemotherapy. However, some hepatoblastomas develop resistance to chemotherapy during the initial neoadjuvant chemotherapy or after tumor recurrence, and the molecular determinants of cisplatin resistance are yet to be discovered. In contrast to hepatoblastomas, pediatric HCCs respond poorly to chemotherapy, and as in adults, they have a poor prognosis if not completely removed by surgery. There is thus an urgent need for new therapeutic strategies to overcome this resistance. Now the inventors demonstrate that Elimusertib and Cisplatin combination shows synergistic efficacy on tumor cell viability inhibition in pediatric liver cancer cell lines. The present invention thus relates to the combination of cisplatin and Elimusertib for the treatment of pediatric liver cancers.

This invention discloses the application of total paeoniflorin in the preparation of drugs for the treatment of head and neck squamous cell carcinoma, belonging to the field of biomedical technology. Addressing the bottlenecks in current treatments for head and neck squamous cell carcinoma, such as high toxicity of radiotherapy and chemotherapy, low response rates to immunotherapy, and easy resistance to targeted drugs, this invention provides a method for preparing total paeoniflorin and a drug-loaded preparation technology based on hydrogels obtained from modified chitosan. Total paeoniflorin can dose-dependently inhibit the proliferation rate, colony formation ability, and in vitro migration ability of SCC7, FADU, and CAL27 head and neck squamous cell carcinoma cell lines, and significantly induce apoptosis. This invention utilizes the multi-target effects of total paeoniflorin to exert anti-head and neck squamous cell carcinoma effects through modulation of the tumor microenvironment and enhancement of immune surveillance. Furthermore, the loaded drug exhibits good sustained-release properties and biosafety, providing a new, highly effective, and low-toxicity strategy for the treatment of head and neck squamous cell carcinoma, and has significant clinical application value.

The invention discloses a human gallbladder cancer cell line and application thereof, and relates to the technical field of cells. The human gallbladder cancer cell line disclosed by the invention is named as a human gallbladder cancer cell line IIAIM-GBC021A6 Homo sapiens, the human gallbladder cancer cell line is preserved in the China Center for Type Culture Collection on February 14, 2025, and the preservation number is CCTCC (China Center for Type Culture Collection) NO: C202559. The human gallbladder cancer cell line IIAIM-GBC021A6Homo sapiens is stable in character, has strong proliferation ability, scratch healing ability, migration ability and in-vitro tumor formation ability, and has different sensitivities to different chemotherapeutic drugs such as cis-platinum, carboplatin, gemcitabine, oxaliplatin, 5-fluorouracil (5-Fu) and the like.

The invention provides a primary cell culture method for constructing a lung cancer cell line by using a micro-tumor PTC (Positive Temperature Coefficient) in-vitro model. PTC is a 3D tumor microsphere which is formed by performing digestion pretreatment on a tumor tissue from a patient and performing self-assembly again in an in-vitro liquid culture medium. The PTC micro-tumor comprises a plurality of cell types such as tumor cells, fibroblasts and immune cells derived from epithelium in original tissues, and has the advantages of short self-assembly period, high culture success rate and the like. The human-derived lung cancer cell line is constructed by utilizing PTC, so that the time cost can be shortened while bacterial pollution is reduced, the culture success rate is improved, and the characteristics and multiplication capacity of a primary lung cancer cell line are reserved.

The invention belongs to the field of medicines, and particularly relates to a construction method of an EBV positive immune reconstruction xenotransplantation tumor model. The method comprises the following steps: taking an SPF-level female severe immunodeficiency mouse, adapting to the environment for 7 + / -3 days, then performing caudal vein injection of human peripheral blood mononuclear cells, and subcutaneously transplanting a human EBV positive gastric cancer cell line AGS / EBV to the right armpit of the mouse next day. The EBV positive immune reconstruction xenotransplantation tumor model provided by the invention has remarkable advantages in the aspects of simulating a human immune system, shortening tumor formation time, revealing that EBV has dual functions of'immune reconstruction-tumor promotion ', supporting treatment strategy development and the like, and an efficient and accurate tool and method are provided for research and treatment of EBV related gastric cancer.

The invention belongs to the technical field of tumor model construction, and discloses a lung adenocarcinoma animal model with high bone metastasis, a cell line and a construction method and application thereof. The lung adenocarcinoma animal model with high bone metastasis is provided through multi-generation in-vivo directional screening, and the construction method is efficient, controllable, high in repeatability, capable of remarkably improving the tumor formation efficiency and rate, capable of being applied to immune healthy mice, low in cost and high in stability. And further extracting tumor cells from the bone metastasis lesion of the animal model to obtain the mouse lung adenocarcinoma cell line with high bone metastasis. The cell line has the advantages of being excellent in bone metastasis performance, stable in phenotype, heritable and the like, can be connected with an existing research system, has universality and economical efficiency, and can efficiently meet the requirement of bone metastasis mechanism research on a high-specificity model. The method can be applied to the fields of construction of tumor animal models or cell lines of bone metastasis, screening or development of lung adenocarcinoma drugs and the like.

The application provides a synthesis method and antitumor application of several furanopyrimidine-ibuprofen hybrid derivatives, which are linked by aza-wittig reaction, intramolecular cyclization, substitution reaction, hydrolysis and acidification reaction and the like, and a fused triazole, a hydrazide, a bis-hydrazide and an oxadiazole are used as a bond bridge key, so that different series of furanopyrimidine-ibuprofen hybrid derivatives are synthesized in a simple and efficient manner. The CCK8 method in vitro pharmacodynamics test proves that the target compound has proliferation inhibition activity on A549 lung cancer cells and HepG2 liver cancer cell lines. Test results show that the target compound shows good proliferation inhibition activity on the two kinds of cells, and the structural formula is as follows:

The present invention relates to anticancer drug-resistant and sensitive liver cancer cell lines, and a method for screening liver cancer therapeutic agents by using same. Specifically, provided are a liver cancer cell line PLLC15 (Accession No. 00000) that does not have sorafenib resistance and / or a liver cancer cell line PLLC15_Sora (Accession No. 00000) that has sorafenib resistance, or a composition for screening anticancer agents including one or more thereof, and a method for screening anticancer agents, and thus an anticancer immunotherapeutic agent or method using immune function of an experimental animal can be screened and time and cost can be reduced by reviewing in advance a sorafenib resistance problem in the development stage of liver cancer therapeutic agents.

The invention discloses a reagent combination or a kit for preparing gamma delta T cells and application of the reagent combination or the kit. In the gamma delta T cell population obtained by the invention, most cells show CD4-CD8a-double negative phenotypes, part of the cells express CD56, and TCR alpha beta and CD41a are not expressed at all, which are consistent with the phenotypes of natural human gamma delta T cells. The gamma delta T cell obtained by the invention has the capability of secreting TNF-alpha and IL-2 cell factors. The gamma delta T cell obtained by the invention has a relatively strong cytotoxic effect on liver cancer cell lines, such as HepG2 cells and Huh-7 cells. The gamma delta T cells can effectively inhibit the proliferation of cancer cells, but have little influence on normal cells, and show high targeting and selectivity.

The invention discloses a method for promoting proliferation and migration of liver cancer cells through hypoxia induction of ACO2 nucleation, and relates to the field of cells. Comprising the following steps: cell culture and passage: placing cells in a complete medium of a DMEM (dulbecco modified eagle medium), culturing under culture conditions, then performing passage, selecting hepatoma carcinoma cell line PLC5 cells, and culturing the hepatoma carcinoma cell line PLC5 cells in a culture medium containing 10% of fetal calf serum and 1% of streptomyces penicillium; constructing plasmids: selecting the plasmids and constructing the plasmids; transfecting the cells, namely transfecting the cultured and subcultured cells; detecting the condition that the plasmids enter the cells through an EdU experiment; detecting the expression of related proteins through immunofluorescent staining; detecting cell migration through a scratch experiment; cell invasion is detected through a Transwell experiment; and counting results. The action mechanism of the ACO2 for nuclear metastasis in liver cancer cells and the influence of the ACO2 on HCC can be accurately determined, so that the application has important clinical significance on a new treatment direction.

The invention discloses a macaque skin squamous carcinoma cell line MCSCC14397 and application of the macaque skin squamous carcinoma cell line MCSCC14397. The macaque skin squamous carcinoma cell line is named as macaque skin squamous carcinoma cell line MCSCC14397, and the preservation number of the macaque skin squamous carcinoma cell line is CCTCC (China Center For Type Culture Collection) NO: C2025156. The cell line disclosed by the invention has similar protein expression with primary tumor tissues, has chromosome abnormal karyotype, in-vitro tumor formation capability and stable proliferation characteristics, and simultaneously shows remarkable genome instability (such as high-frequency Cgt, T mutation and structural variation) and inflammation signal activation. The MYO10 gene expression in the cell line is up-regulated and drives DNA damage reaction and inflammatory factor expression, and unique advantages are provided for application of the cell line in skin squamous cell carcinoma mechanism research, drug screening and drug efficacy evaluation. The cell line disclosed by the invention can be used as an effective cell model, can be used for establishing a xenotransplantation animal model, and can provide a research basis for deeply researching the occurrence, development, metastasis mechanism and drug resistance mechanism of human skin squamous cell carcinoma as well as innovative drug development and screening.

The invention relates to the field of tumor cell lines, and provides a mouse head and neck squamous carcinoma cell line as well as a construction method and application thereof, the mouse head and neck squamous carcinoma cell line is named as 4N-MS1 and preserved in Guangdong Microbial Culture Collection Center, and the preservation number is GDMCC NO: 65741. The construction method comprises the following steps: S1, inducing mouse oral mucosa canceration by using a chemical reagent; s2, cutting tumor tissues through an operation, cutting the tumor tissues into pieces, further cutting the tumor tissues into pieces through enzymatic dissociation, preparing a single-cell suspension, and transferring the cells into a pore plate for culture to obtain primary tumor cells; s3, purifying the primary tumor cells by an enzyme digestion method to obtain purified primary tumor cells; s4, transfecting the purified primary generation head and neck squamous cell carcinoma tumor cells with viruses to obtain the mouse head and neck squamous cell carcinoma cell line which grows stably. The cell line has the advantages that the cell line is high in purity, high in growth speed and high in tumor formation capacity in a mouse body, and a powerful tool is provided for later research on mechanisms of tumor immune response, escape and the like on an HNSCC mouse model and related treatment targets of an immune system.

The invention belongs to the technical field of microbial animal cell lines, and particularly relates to a mouse intrahepatic bile duct cancer cell line mICC-K and application thereof. The mouse intrahepatic bile duct cancer cell line mICC-K is preserved in the China Center for Type Culture Collection on January 23, 2025, and the preservation number of the mouse intrahepatic bile duct cancer cell line mICC-K is CCTCC NO: C202538. The mouse intrahepatic cholangiocarcinoma spontaneous tumor is induced through AKT, YAP and SB plasmid systems by utilizing a high-pressure hydrodynamic method caudal vein plasmid injection method, so that the mouse intrahepatic cholangiocarcinoma cell line is obtained, and meanwhile, a KRASG12D mutation site is introduced, so that the blank of lack of a stable mouse in-vivo and in-vitro model in the current domestic intrahepatic cholangiocarcinoma research is filled, and the mouse intrahepatic cholangiocarcinoma cell line is developed. In addition, a stable model is provided for drug target research aiming at KRAS mutation.

The application discloses a rhesus monkey skin squamous carcinoma cell line MCSCC14397 and application thereof. The rhesus monkey skin squamous carcinoma cell line is named as the rhesus monkey skin squamous carcinoma cell line MCSCC14397, and the preservation number is CCTCC NO: C2025156. The cell line of the application has similar protein expression as primary tumor tissue, has abnormal karyotype, in-vitro tumorigenic ability and stable proliferation characteristics, and simultaneously shows significant genomic instability (such as high-frequency C>T mutation, structural variation) and inflammation signal activation. MYO10 gene expression is up-regulated in the cell line and drives DNA damage response and inflammation factor expression, which provides unique advantages for the application of the cell line in skin squamous carcinoma mechanism research, drug screening and efficacy evaluation. The cell line of the application can be used as an effective cell model, can establish a xenotransplantation animal model, and can provide a research basis for in-depth research on the occurrence, development, metastasis mechanism and drug resistance mechanism of human skin squamous carcinoma and innovative drug development and screening.

The invention discloses a linear long-chain compound containing valine thiazole as well as a preparation method and application of the linear long-chain compound, and belongs to the technical field of medicinal chemistry. The structure of the linear long-chain compound containing valine thiazole is shown in the specification. The valinethiazole-containing linear long-chain compound has the beneficial effects that the valinethiazole-containing linear long-chain compound provided by the invention is novel in structure, the compound 6, the compound 9, the compound 11 and the compound 13 are good in safety, particularly, the MDR reverse activity of the compound 9 on a human oral epidermoid cancer cell line KBV is higher than that of a positive control drug verapamil, the effect is improved by 8 times compared with that of verapamil, and the compound 6, the compound 9, the compound 11 and the compound 13 can be used for preparing the valinethiazole-containing linear long-chain compound. Compared with Dysoxylactam A, the reverse multiple of the Dysoxylactam A is obviously improved from 174.3 times to 288.5 times, and the Dysoxylactam A has the application prospect of becoming a novel tumor drug resistance reversal agent.

The invention discloses an antibody coupling medicine LZU-WZLY-WYR02 as well as a preparation method and application thereof, and belongs to the technical field of medicines. The drug is composed of three parts: a humanized monoclonal antibody targeting FGFR3, a linker GGFG capable of being subjected to enzyme digestion, and cytotoxin 7-ethyl-10-fluorocamptothecin. The linker GGFG is connected with toxin through a carbonate bond, and is coupled to a lysine site of an antibody through an amido bond to form an ADC drug which is clear in structure, uniform in DAR and good in stability. The drug shows excellent tumor targeting and antitumor activity in FGFR3 high-expression bladder cancer cell lines (such as T24 and UMUC-3) and animal models (CDX and PDX), has low toxic and side effects, and has important clinical application value.